Effect of saxagliptin on nonalcoholic fatty liver in patients with diabetes mellitus

VernacularTitle:DPP-4抑制剂沙格列汀对糖尿病非酒精性脂肪肝的作用研究
Author: Chengjian WANG ; Rongxi HUANG ; Yingsong JIANG ; Keping YU
Keywords: saxagliptin; diabetes mellitus,type 2; nonalcobolic fatty liver disease
From: Chongqing Medicine 2017;46(11):1490-1491,1494
CountryChina
Language:Chinese
Abstract: Objective To observe the effect and efficacy of DPP-4 inhibitor saxagliptin on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus.Methods Forty patients with newly diagnosed with type 2 diabetes complicated with NAFLD were divided into two groups:the saxagliptin group and the metformin group.On the basis of dietary and exercise therapies,the saxagliptin group received 0.005 g of saxagliptin daily and the metformin treatment group received 0.85-1.70 g of metformin daily.The levels of glycosylated hemoglobin(HbA1 c),triglyceride (TG),blood pressure (BP),alanine aminotransferase (ALT),liver CT and liver/spleen CT were observed before and 3 months after treatment.Results After treatment for 3 months,the TG,ALT,liver CT and liver / spleen CT of the metformin group and the saxagliptin group were significantly higher than those before treatment(P＜0.05).There was no significant difference in the TG,ALT and liver CT values between the two groups(P＞ 0.05).Conclusion In the state of diabetes mellitus complicate with nonalcoholic fatty liver,saxagliptin has a certain effect on relieving fatty liver.